Compare Enbridge Inc (ENB) vs GSK plc (GSK) Price & Performance

ENB trades at $56.20, up 0.55% with a bullish technical outlook. Recent earnings show mixed results with Q1 2026 beating estimates but Q3 2025 missing. The company maintains strong cash flow from operations of $12.27B in 2025 and a 5.1% dividend yield. Revenue grew to $65.19B in 2025, with net income margin at 10%. Analyst consensus is evenly split between Buy and Hold ratings.

Outlook remains positive due to $28B in growth projects and stable dividends, but risks include high debt levels (debt-to-asset ratio 48.81% in 2025) and sensitivity to energy market volatility. The stock offers income appeal but faces execution risks on capital expenditures.

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.